Second Sight Medical Products Share Price

Equities

EYES

US81362J3086

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
1.63 USD -3.83% Intraday chart for Second Sight Medical Products -4.12% -28.51%
Sales 2020 - Sales 2021 - Capitalization 64.24M 5.14B
Net income 2020 -14M -1.12B Net income 2021 -8M -640M EV / Sales 2020 -
Net cash position 2020 977K 78.21M Net cash position 2021 69.36M 5.55B EV / Sales 2021 -
P/E ratio 2020
-2.59 x
P/E ratio 2021
-6 x
Employees 15
Yield 2020 *
-
Yield 2021
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Vivani Medical Starts Nasdaq Trading Lower MT
Second Sight Medical Products, Inc.(NasdaqCM:EYES) dropped from NASDAQ Composite Index CI
Second Sight Medical Completes Merger With Nano Precision Medical; Changes Name to Vivani Medical MT
Nano Precision Medical, Inc. completed the acquisition of Second Sight Medical Products, Inc. in a reverse merger transaction. CI
Second Sight Medical Products Starts Trading on Split-Adjusted Basis; Shares Down MT
Second Sight Medical Products, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Second Sight Medical Products, Inc. Announces Resignation of Edward Randolph as its Chief Operating Officer, Effective August 19, 2022 CI
Second Sight Medical Products, Inc. has Changed its Name to Vivani Medical, Inc CI
Second Sight Medical Products Receives $1.1 Million of Funding for Visual Cortical Prosthesis Trial MT
Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study CI
Second Sight Medical Products, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
North American Morning Briefing : Dow Futures -2- DJ
North American Morning Briefing : Stock Futures -3- DJ
Transcript : Nano Precision Medical, Inc., Second Sight Medical Products, Inc. - M&A Call
Second Sight Medical Products to Acquire Nano Precision Medical in All-Stock Deal MT
More news
1 day-3.83%
Current month-28.51%
Current year-28.51%
More quotes
3 years
1.62
Extreme 1.62
22.92
5 years
1.62
Extreme 1.62
60.00
10 years
1.62
Extreme 1.62
576.48
More quotes
Date Price Change Volume
26/04/24 1.63 -3.83% 117,480
25/04/24 1.695 -2.02% 92,357
24/04/24 1.73 -3.89% 53,869
23/04/24 1.8 +7.78% 93,170
22/04/24 1.67 -1.76% 137,987

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.
Sector
-
More about the company